By preventing T lymphocytes with self-reactive receptors from entering target tissues, pharmacological agents targeting the S1P/S1PR1 axis have shown efficacy in the treatment of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease (IBD) [28, 29]. Here, S1PR1 is linked to inflammatory bowel disease.